Article
Clinical Neurology
Shuaishuai Gong, Guosheng Cao, Fang Li, Zhuo Chen, Xuewei Pan, Huifen Ma, Yuanyuan Zhang, Boyang Yu, Junping Kou
Summary: The study suggests that NMMHC IIA plays a crucial role in ischemic stroke by maintaining the integrity of the cerebral endothelial barrier, making it a potential therapeutic target for ischemic stroke.
Review
Clinical Neurology
Osvaldo P. Almeida, Monique P. Singulani, Andrew H. Ford, Maree L. Hackett, Christopher Etherton-Beer, Leon Flicker, Graeme J. Hankey, Vanessa J. R. De Paula, Camila T. Penteado, Orestes Forlenza
Summary: Animal studies consistently show neuroprotective effects of lithium in stroke models, while human studies have limited and inconclusive evidence. Treatment with lithium in rodents is associated with reduced stroke volume, decreased apoptosis, and improved post-stroke function, but human studies on this topic remain sparse and uncertain.
Article
Multidisciplinary Sciences
Erdem Pulcu, Kate E. A. Saunders, Catherine J. Harmer, Paul J. Harrison, Guy M. Goodwin, John R. Geddes, Michael Browning
Summary: The affective variability of bipolar disorder (BD) is different from that of borderline personality disorder (BPD), and lithium treatment increases the volatility of positive affect.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
(2022)
Letter
Clinical Neurology
Mustafa Akkus
Summary: This case suggests that lithium-induced tardive dyskinesia may be reversible in a dose-dependent manner.
JOURNAL OF AFFECTIVE DISORDERS
(2022)
Article
Biochemistry & Molecular Biology
Himanshu K. Mishra, Noelle M. Ying, Angelica Luis, Heather Wei, Metta Nguyen, Timothy Nakhla, Sara Vandenburgh, Martin Alda, Wade H. Berrettini, Kristen J. Brennand, Joseph R. Calabrese, William H. Coryell, Mark A. Frye, Fred H. Gage, Elliot S. Gershon, Melvin G. McInnis, Caroline M. Nievergelt, John I. Nurnberger, Paul D. Shilling, Ketil J. Oedegaard, Peter P. Zandi, R. Kelsoe John, David K. Welsh, Michael J. McCarthy
Summary: Neuronal circadian rhythm abnormalities are present in patients with bipolar disorder, with the most pronounced deficits observed in individuals who do not respond to lithium treatment. Stimulation of entrainment pathways may partly reverse these rhythm deficits.
MOLECULAR PSYCHIATRY
(2021)
Article
Clinical Neurology
Gregory Jones, Carola Rong, Courtney M. Vecera, Christopher Gurguis, Roshan Chudal, Rushaniya Khairova, Edison Leung, Ana C. Ruiz, Lokesh Shahani, Marcus Zanetti, Rafael T. de Sousa, Geraldo Busatto, Jair Soares, Wagner F. Gattaz, Rodrigo Machado-Vieira
Summary: Lithium may play an important role in treating comorbid anxiety in bipolar disorder, both as adjunct and monotherapy. Lower doses of lithium may provide equivalent efficacy and enhance tolerability and compliance.
JOURNAL OF AFFECTIVE DISORDERS
(2022)
Article
Clinical Neurology
Maurizio Pompili, Isabella Berardelli, Salvatore Sarubbi, Elena Rogante, Luca Germano, Giuseppe Sarli, Denise Erbuto, Ross J. Baldessarini
Summary: This study observed 260 patients with bipolar or major depressive disorder and found that lithium treatment reduced hospitalization rates and morbidity. Factors associated with hospitalization during lithium treatment included concurrent use of antipsychotic medication, suicide attempts during lithium treatment, lifetime substance abuse, and previous psychiatric hospitalization before starting lithium.
JOURNAL OF AFFECTIVE DISORDERS
(2023)
Article
Pharmacology & Pharmacy
Rachel Shvartsur, Galila Agam, Alla Shnaider, Sarit Uzzan, Ahmad Nassar, Adi Jabarin, Naim Abu-Freha, Karen Meir, Abed N. Azab
Summary: Chronic low-dose aspirin can mitigate the typical renal side effects of standard-dose lithium and enhance the beneficial behavioral effects of low-dose lithium therapy without aggravating its toxicity.
Article
Medicine, General & Internal
Joseph F. Hayes, David P. J. Osborn, Emma Francis, Gareth Ambler, Laurie A. Tomlinson, Magnus Boman, Ian C. K. Wong, John R. Geddes, Christina Dalman, Glyn Lewis
Summary: This study developed a model to predict the risk of chronic kidney disease in patients with bipolar disorder following lithium treatment initiation, identifying individuals with a high-risk trajectory of kidney function. The model showed that individuals with characteristics such as younger age, female gender, and lower baseline eGFR were at increased risk of a poor eGFR trajectory, regardless of lithium duration and toxicity.
Review
Biochemistry & Molecular Biology
Natasha Ting Lee, Lin Kooi Ong, Prajwal Gyawali, Che Mohd Nasril Che Mohd Nassir, Muzaimi Mustapha, Harshal H. Nandurkar, Maithili Sashindranath
Summary: Cerebral endothelium plays a crucial role in regulating various physiological functions to maintain the health of the central nervous system. Cardiovascular risk factors contribute to cerebral endothelial dysfunction, leading to impaired vasodilation, aggravated inflammatory responses, increased oxidative stress, and vascular proliferation.
Article
Psychiatry
Keita Idemoto, Tomihisa Niitsu, Tatsuki Hata, Tamaki Ishima, Sumiko Yoshida, Kotaro Hattori, Tadasu Horai, Ikuo Otsuka, Hidenaga Yamamori, Shigenobu Toda, Yosuke Kameno, Kiyomitsu Ota, Yasunori Oda, Atsushi Kimura, Tasuku Hashimoto, Norio Mori, Mitsuru Kikuchi, Yoshio Minabe, Ryota Hashimoto, Akitoyo Hishimoto, Kazuyuki Nakagome, Kenji Hashimoto, Masaomi Iyo
Summary: The study revealed that serum levels of glial cell line-derived neurotrophic factor (GDNF) were significantly decreased in patients with bipolar disorder (BD) and major depressive disorder (MDD) compared to healthy controls, and remained lower in patients in remission or depressive states after treatment. Furthermore, lower serum GDNF levels were associated with a higher clinical severity and better response to lithium therapy in BD patients.
PSYCHIATRY RESEARCH
(2021)
Article
Clinical Neurology
Lars Vedel Kessing, Simon Christoffer Ziersen, Thomas Gerds, Esben Budtz-Jorgensen
Summary: This nationwide population-based longitudinal register linkage study aimed to investigate the long-term response to lithium in patients with bipolar disorder with and without comorbid epilepsy. The study also aimed to compare differences in responses between lithium, valproate, and lamotrigine within patients with comorbid bipolar disorder and epilepsy. The findings suggest that valproate and lamotrigine should be given priority in these patients.
JOURNAL OF AFFECTIVE DISORDERS
(2022)
Review
Biochemistry & Molecular Biology
Daniela Jaime Garcia, Audrey Chagnot, Joanna M. Wardlaw, Axel Montagne
Summary: Small vessel disease (SVD) is a prevalent disorder of the brain's microvessels and is a common cause of dementia and strokes. Recent evidence suggests that endothelial dysfunction and a compromised blood-brain barrier play a key role in the development and progression of SVD. Understanding the molecular mechanisms underlying endothelial dysfunction in SVD could lead to better diagnostic tools and potential therapeutic interventions.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Article
Pharmacology & Pharmacy
Rachel Shvartsur, Galila Agam, Sarit Uzzan, Abed N. Azab
Summary: Mounting evidence suggests that immune-system dysfunction and inflammation play a role in the pathophysiology and treatment of mood disorders. This study found that chronic combined treatment attenuated LPS-induced hypothermia and reduced cytokine levels, suggesting a potential approach for treating inflammation-related mental illness. The treatment also showed antidepressant-like effects.
Review
Pharmacology & Pharmacy
Markus Woehr
Summary: Rats emit 50-kHz ultrasonic vocalizations in appetitive situations, particularly elicited by d-amphetamine, and can serve as a reliable measure for assessing elevated mood in rats. Pharmacological interventions can modulate this vocalization, providing new insights into manic behaviors and potential therapeutic targets.
BRITISH JOURNAL OF PHARMACOLOGY
(2022)
Article
Neurosciences
Gwen van der Wijk, Jacqueline K. Harris, Stefanie Hassel, Andrew D. Davis, Mojdeh Zamyadi, Stephen R. Arnott, Roumen Milev, Raymond W. Lam, Benicio N. Frey, Geoffrey B. Hall, Daniel J. Muller, Susan Rotzinger, Sidney H. Kennedy, Stephen C. Strother, Glenda M. MacQueen, Andrea B. Protzner
Summary: By studying a large group of MDD patients and controls using fMRI data, differences in functional connectivity in patients were identified. Baseline connectivity of the anterior/posterior cingulate and insula seeds could differentiate patients with different treatment outcomes, highlighting features that might predict remission prior to pharmacotherapy.
Editorial Material
Dentistry, Oral Surgery & Medicine
Dustin J. Mueller, Erica Mueller
JOURNAL OF DENTAL EDUCATION
(2022)
Article
Geriatrics & Gerontology
Chad A. Bousman, Anita Oomen, Chaten D. Jessel, Rajesh R. Tampi, Brent P. Forester, Harris A. Eyre, Helen Lavretsky, Daniel J. Muller
Summary: This study assessed the perspectives on pharmacogenetic testing among members of the American Association of Geriatric Psychiatry. The findings indicated that although most respondents had used PGx testing, they were uncertain about its clinical usefulness in late-life mental health. There were also uncertainties related to ethical obligation and legal liability when interpreting and using PGx testing results. The respondents strongly advocated for the development of clinical and legal guidelines to promote the use of PGx testing in older adults.
AMERICAN JOURNAL OF GERIATRIC PSYCHIATRY
(2022)
Article
Psychiatry
Chad A. Bousman, Gouri Mukerjee, Xiaoyu Men, Ruslan Dorfman, Daniel J. Muller, Roger E. Thomas
CANADIAN JOURNAL OF PSYCHIATRY-REVUE CANADIENNE DE PSYCHIATRIE
(2022)
Review
Biochemistry & Molecular Biology
Lara E. Murphy, Trehani M. Fonseka, Chad A. Bousman, Daniel J. Mueller
Summary: There are significant individual differences in the therapeutic effectiveness and adverse effects of antidepressant and antipsychotic medications, which can be partially explained by genetic variation. Evidence-based guidelines are available for pharmacogenetic-guided prescribing of these medications, but key barriers such as economic, educational, regulatory, and ethical issues need to be addressed for optimal patient care outcomes.
MOLECULAR PSYCHIATRY
(2022)
Article
Neurosciences
Prabhjot Dhami, Lena C. Quilty, Benjamin Schwartzmann, Rudolf Uher, Timothy A. Allen, Stefan Kloiber, Raymond W. Lam, Glenda MacQueen, Benicio N. Frey, Roumen Milev, Daniel J. Mueller, Stephen C. Strother, Pierre Blier, Claudio N. Soares, Sagar V. Parikh, Gustavo Turecki, Jane A. Foster, Susan Rotzinger, Sidney H. Kennedy, Faranak Farzan
Summary: The neurobiological correlates of response inhibition can predict the response of patients with major depressive disorder (MDD) to pharmacological and cognitive behavioral therapy treatment. The integrity of response inhibition may be crucial for the success of treatment for MDD. Electrophysiological correlates of response inhibition may serve as a general prognostic marker for treatment response in MDD.
BIOLOGICAL PSYCHIATRY-COGNITIVE NEUROSCIENCE AND NEUROIMAGING
(2023)
Review
Genetics & Heredity
Farhana Islam, Daniel Hain, David Lewis, Rebecca Law, Lisa Brown, Julie-Anne Tanner, Daniel J. Muller
Summary: Clozapine is effective for treatment-resistant schizophrenia, but its under-utilization and delayed initiation are common. This study identified genetic variations associated with clozapine-induced agranulocytosis, which can help predict patient risk and personalize treatment.
PHARMACOGENOMICS JOURNAL
(2022)
Article
Pharmacology & Pharmacy
Helena K. Kim, Gwyneth Zai, Daniel J. Mueller, Muhammad Husain, Raymond W. Lam, Benicio N. Frey, Claudio N. Soares, Sagar Parikh, Roumen Milev, Jane A. Foster, Gustavo Turecki, Faranak Farzan, Benoit H. Mulsant, Sidney H. Kennedy, Shreejoy J. Tripathy, Stefan Kloiber
Summary: This study explores the relationship between the endocannabinoidome and major depressive disorder (MDD), and identifies lower methylation levels of the DAGLA gene as a potential marker for treatment outcomes in MDD. Further research is needed to explore the significance of DAGLA methylation in MDD treatment.
PHARMACOPSYCHIATRY
(2022)
Article
Chemistry, Medicinal
Liv S. Thiele, Kazi Ishtiak-Ahmed, Janne P. Thirstrup, Esben Agerbo, Carin A. T. C. Lunenburg, Daniel J. Muller, Christiane Gasse
Summary: This study evaluates the impact of CYP2C19 and CYP2D6 gene variants on antidepressant treatment in patients with depression. The results indicate that these gene variants are associated with an increased risk of treatment switching, emergency department contacts, and suicide attempt/self-harm in children, adolescents, and young adults using certain antidepressant medications.
Review
Pharmacology & Pharmacy
Lisa C. Brown, Joseph D. Stanton, Kanika Bharthi, Abdullah Al Maruf, Daniel J. Muller, Chad A. Bousman
Summary: This study systematically reviewed and meta-analyzed the association between PGx-guided antidepressant therapy and depressive symptom remission in MDD patients. The results suggest that PGx-guided antidepressant therapy is modestly but significantly associated with an increase in depressive symptom remission in adults with MDD.
CLINICAL PHARMACOLOGY & THERAPEUTICS
(2022)
Article
Psychology, Clinical
Mehri Sajjadian, Rudolf Uher, Keith Ho, Stefanie Hassel, Roumen Milev, Benicio N. Frey, Faranak Farzan, Pierre Blier, Jane A. Foster, Sagar Parikh, Daniel J. Mueller, Susan Rotzinger, Claudio N. Soares, Gustavo Turecki, Valerie H. Taylor, Raymond W. Lam, Stephen C. Strother, Sidney H. Kennedy
Summary: Predicting treatment outcomes for major depressive disorder can be improved by combining clinical, neuroimaging, and molecular data. Early measurement during treatment can increase precision, but adding more features does not necessarily enhance prediction accuracy.
PSYCHOLOGICAL MEDICINE
(2023)
Article
Psychiatry
Farhana Islam, Victoria S. Marshe, Leen Magarbeh, Benicio N. Frey, Roumen Milev, Claudio N. Soares, Sagar Parikh, Franca Placenza, Stephen C. Strother, Stefanie Hassel, Valerie H. Taylor, Francesco Leri, Pierre Blier, Rudolf Uher, Faranak Farzan, Raymond W. Lam, Gustavo Turecki, Jane A. Foster, Susan Rotzinger, Sidney H. Kennedy, Daniel J. Mueller
Summary: Cytochrome P450 drug-metabolizing enzymes, specifically CYP2C19 and CYP2D6 gene variants, have an impact on antidepressant outcomes. Poor metabolizers of CYP2C19 and CYP2D6 show less symptom improvement during treatment with escitalopram alone and are more likely to experience central nervous system side effects when taking escitalopram alone or in combination with aripiprazole.
TRANSLATIONAL PSYCHIATRY
(2022)
Article
Neuroimaging
Jacqueline K. Harris, Stefanie Hassel, Andrew D. Davis, Mojdeh Zamyadi, Stephen R. Arnott, Roumen Milev, Raymond W. Lam, Benicio N. Frey, Geoffrey B. Hall, Daniel J. Muller, Susan Rotzinger, Sidney H. Kennedy, Stephen C. Strother, Glenda M. MacQueen, Russell Greiner
Summary: Previous intervention studies have used fMRI data to predict the antidepressant response of patients with MDD. However, the limited scope of these studies may not accurately reflect real-world situations. This study suggests that collecting fMRI data before and shortly after treatment initiation can lead to improved predictive models.
NEUROIMAGE-CLINICAL
(2022)
Review
Pharmacology & Pharmacy
Raghunath Singh, Nicolette Stogios, Emily Smith, Jiwon Lee, Kateryna Maksyutynsk, Emily Au, David C. Wright, Giada De Palma, Ariel Graff-Guerrero, Philip Gerretsen, Daniel J. Muller, Gary Remington, Margaret Hahn, Sri Mahavir Agarwal
Summary: This scoping review examines the role of gut microbiota (GMB) in the pathophysiology of schizophrenia (SCZ) and metabolic alterations associated with antipsychotics (APs). The findings suggest that changes in GMB composition are associated with SCZ pathogenesis and AP-induced metabolic perturbations. Additionally, prebiotic and probiotic formulations show potential therapeutic benefits in improving SCZ symptoms and attenuating AP-induced metabolic alterations.
THERAPEUTIC ADVANCES IN PSYCHOPHARMACOLOGY
(2022)
Article
Neurosciences
Oliver Pain, Karen Hodgson, Vassily Trubetskoy, Stephan Ripke, Victoria S. Marshe, Mark J. Adams, Enda M. Byrne, Adrian I. Campos, Tania Carrillo-Roa, Annamaria Cattaneo, Thomas D. Als, Daniel Souery, Mojca Z. Dernovsek, Chiara Fabbri, Caroline Hayward, Neven Henigsberg, Joanna Hauser, James L. Kennedy, Eric J. Lenze, Glyn Lewis, Daniel J. Mueller, Nicholas G. Martin, Benoit H. Mulsant, Ole Mors, Nader Perroud, David J. Porteous, Miguel E. Renteria, Charles F. Reynolds, Marcella Rietschel, Rudolf Uher, Eleanor M. Wigmore, Wolfgang Maier, Naomi R. Wray, Katherine J. Aitchison, Volker Arolt, Bernhard T. Baune, Joanna M. Biernacka, Guido Bondolfi, Katharina Domschke, Masaki Kato, Qingqin S. Li, Yu-Li Liu, Alessandro Serretti, Shih-Jen Tsai, Gustavo Turecki, Richard Weinshilboum, Andrew M. McIntosh, Cathryn M. Lewis
Summary: Antidepressant response is influenced by common genetic variation, has a genetic overlap with schizophrenia and educational attainment, and provides a useful resource for future research.
BIOLOGICAL PSYCHIATRY: GLOBAL OPEN SCIENCE
(2022)